Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity

Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300

Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC Clinical Trial of LP-300 in Never Smoker NSCLC Patients

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC Clinical Trial of LP-300 in Never Smoker NSCLC Patients

Non-Smokers Keep Getting Lung Cancer. Dallas’ Lantern Pharma Is Using AI to Fight Back

Lung Cancer Treatment for Never Smokers: The HARMONIC Phase 2 Trial and LP-300

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

LP-300 Shows Promise in Treating Advanced Lung Cancer in Never Smokers

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

LP-300 Plus Chemo Yields Early Efficacy Results in Never-Smokers With NSCLC

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never Smokers into Japan and Taiwan

Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300

Lantern Pharma's New Phase 2 Clinical Trial –Harmonic™ — Approved for Launch by the FDA

Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial (Harmonic™) for LP-300 in Never Smokers with Non-Small Cell Lung Cancer

Lantern Pharma Gets FDA Nod to Begin Phase II Trial of LP-300 in Biomarker-Defined NSCLC

Lantern Pharma Enters into Strategic Collaboration with Deep Lens; Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial for Never Smokers with Non-Small Cell Lung Cancer

Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives